Valens Company
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
At a composite of 44, Valens Company scores as Neutral, with conviction of 2 out of 5 backing the assessment. The composite is a fixed blend of four pillars — fundamentals at 35 percent, regulatory at 25, market at 25, and editorial at 15 — and each contribution is inspectable. The strongest contribution comes from the fundamentals pillar at 49, and pulls the composite toward the lower edge of the band. Editorial lags at 30, softening what would otherwise be a stronger reading.
Working through the numbers, Valens Company shows reported revenue growth of 15.8 percent year over year, an operating margin of -74.4 percent. Those inputs are the ones that drive the Neutral anchor rather than sentiment. Every input flowing into the pillar table comes from primary regulatory filings, licensed fundamentals data, and institutional pricing feeds, filtered through CIN newsroom density. The 336-ticker CIN universe is scored deterministically, so Valens Company can be compared against the US operator peer set on identical inputs, refreshed on the ingest cycle.
The clearest catalyst is the next quarterly print. Fundamentals contribute 49 of the composite, and either an acceleration in top-line growth or a stabilization of the operating margin would move the score higher; a deterioration on either would compress it.
- IR email
- investors@sndl.com
- IR page
- Investor relations
- CEO
- Zachary George (SNDL Inc.)
- CFO
- Alberto Paredero-Quiros (SNDL Inc.)
- SEC CIK
- 0001859902
- Website
- Company website
- Market cap
- $95.9M
- Enterprise value
- $232.5M
- Price to book
- 1.34
- Price to sales
- 3.79
- EV / EBITDA
- 10.07
- Revenue (TTM)
- $75.8M
- Gross profit (TTM)
- $27.5M
- Operating margin
- -74.4%
- Profit margin
- -58.4%
- Rev growth YoY
- 15.8%
- Return on equity
- -23.1%
- Return on assets
- -13.6%
- EPS (TTM)
- $-0.75
- EPS est. current year
- $-0.44
- Shares outstanding
- 68.1M
- Insider ownership
- 14.5%
- Institutional ownership
- 12.2%
- Beta
- 1.61
- Full-time employees
- 203
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for Valens Company (VLNCF)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Valens Company (VLNCF), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Event-Driven Opportunity. Setup improving. Long-term outperformer detected. (2 bullish signals, 0 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for VLNCF are maintained by Cannabis Investor News and refreshed throughout the trading day.